Abstract: Plasmepsin group of enzymes are key enzymes in the life cycle of malarial parasites. As inhibition of plasmepsins leads to the parasite's death, these enzymes can be utilized as potential drug targets. Although many drugs are available, it has been observed that Plasmodium falciparum, the species that causes most of the malarial infections and subsequent death, has developed resistance against most of the drugs. Based on the cleavage sites of hemglobin, the substrate for plasmepsins, we have designed two compounds (p-nitrobenzoyl-leucine-b-alanine and p-nitrobenzoylleucine-isonipecotic acid), synthesized them, solved their crystal structures and studied their inhibitory effect using experimental and theoretical (docking) methods. In this paper, we discuss the synthesis, crystal structures and inhibitory nature of these two compounds which have a potential to inhibit plasmepsins.
Introduction
Every year, billions of people are infected with malaria and close to 3 million people die because of the disease (1).
Malaria is caused by four major species, Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. Among these four major species, P. falciparum alone accounts for more than 95% of the malaria cases (2) . Although many antimalarial drugs are available, both P. falciparum and P. vivax have developed resistance for almost all the available drugs (3, 4) . Therefore, to find newer antimalarial agents is indeed the need of the hour.
The asexual development of the malarial parasite takes place in human erythrocyte or the red blood cell (RBC).
enzymes are available, none of them are in use as drugs for the treatment of malaria today. We have designed and synthesized two small compounds ( Fig. 1 ) based on the Hb cleavage sites of plasmepsins and also incorporated a bamino acid in one of them and the isonipecotic acid group in the other as alternate strategies for inhibitor design with a view to test the feasibility of developing them as effective antimalarials. To study the interaction of these compounds with plasmepsin I, we have crystallized both the compounds, determined their crystal structures and performed docking studies using the crystal structures, the results of which are presented in this paper.
Experimental Procedures

Synthesis of compounds
The compounds were synthesized by the stepwise solutionphase method. Dicyclo hexylcarbodiamide (DCC) was used for the formation of the peptide bond. 0.7 g (6.42 mm, 2 eq.) of hydrochloride was neutralized, followed by extraction with ethyl acetate and concentration to approximately 5 mL. It was then added to p-(NO 2 )-BaLeu-OH under stirring while maintaining the temperature at 0°C, followed immediately by the addition of DCC/1-hydroxybenzotrizole (HOBt) of 0.70 g (3.21 mm)/0.43 g (3.21 mm). The reaction mixture was allowed to reach room temperature and stirred for 3-4 h. The precipitated dicyclohexylurea was filtered off. The organic layer was washed successively with 2 n HCl (3 · 50 mL), brine (3 · 50 mL), 1 m sodium carbonate (3 · 50 mL) and brine (3 · 50 mL). This layer was then dried over anhydrous sodium sulfate and was evaporated to yield a white solid. The crude peptide was recrystallized from petroleum ether to obtain Asp-12/Asp-13. The sample was purified over silica gel using chloroform-methanol as an elutant to yield 0.96 g (2.63 mm, 82.10%) of Asp-12/Asp-13.
1.0 mm) was dissolved in 5 mL of ethyl acetate and cooled to 0°C in an ice bath. H-Ina-OMe (Ina-isonipecotic acid), isolated from 0.28 g (2.0 mm, 2 eq.) of hydrochloride was neutralized, followed by extraction with ethyl acetate, and concentration to approximately 5 mL. It was then added to p-(NO 2 )-Ba-Leu-OH under stirring while maintaining the temperature at 0°C, followed immediately by the addition of DCC/HOBt of 0.21 g (1.0 mm)/0.14 g (1.0 mm). The reaction mixture was allowed to reach room temperature and stirred for 3-4 h. The precipitated dicyclohexylurea was filtered off.
The organic layer was washed successively with 2 n HCl (3 · 50 mL), brine (3 · 50 mL), 1 m sodium carbonate (3 · 50 mL) and brine (3 · 50 mL). This layer was then dried over anhydrous sodium sulfate and was evaporated to yield a white solid. The crude peptide was recrystalized from petroleum ether to obtain Asp-20/Asp-21. The sample was purified over silica gel using chloroform-methanol as an elutant to yield 0.35 g (0.86 mm, 86.30%) of Asp-20/Asp-21.
Characterization
Elemental analysis of the compounds was carried out using a ThermoFinnigan FLASH EA 1112 CHNS analyser (Thermo Electron Corporation, Waltham, MA, USA) and the 
Results
Crystal structures
The details of crystal system and diffraction and refinement parameters of the two compounds are summarized in Table 1 . The structures were determined by direct methods and the hydrogen atoms were located in difference Fourier maps. Anisotropic thermal parameters of the non-hydrogen atoms were refined in the final cycles of the refinement.
Non-hydrogen atoms with their thermal ellipsoids are shown in Fig. 2 .
The coordinates of non-hydrogen atoms with their equivalent isotropic thermal parameters are given in Table 2 .
Hydrogen bonds in the crystal structures are given in Table 3 .
Asp-12 and Asp-13 crystallize in space group P1 with one molecule each in the asymmetric unit. Two hydrogen bonds exist between these two molecules, made by the nitrogen and the carbonyl carbon atoms of the leucine residue. In addition, the molecules are stabilized in the lattice by two additional intermolecular hydrogen bonds ( Table 3 
